Filana Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Filana Therapeutics, Inc. (FLNA) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-03-03
- Filana Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $0.00.
- Filana Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Filana Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $340.00K.
- Filana Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-03 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-03 |
| 2022-12-31 | $340.00K 10-K · filed 2025-03-03 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |